Stock ANVS ANNOVIS BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Annovis Bio, Inc.

Equities

ANVS

US03615A1088

Market Closed - Nyse
Other stock markets
 04:00:02 2024-06-07 pm EDT 		5-day change 1st Jan Change
6.17 USD -7.50% Intraday chart for Annovis Bio, Inc. -5.80% -67.01%
May. 10 Annovis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 09 Annovis Bio, Inc. Announces Unblinding of the Buntanetap Phase III Data in Parkinson?s Disease CI

Analyst Reco.

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Canaccord Genuity Cuts Price Target on Annovis Bio to $26 From $36, Maintains Buy Rating
MT
Brookline Capital Downgrades Annovis Bio to Hold From Buy, $9 Price Target
MT
Canaccord Genuity Initiates Annovis Bio at Buy With $36 Price Target
MT
HC Wainwright Cuts Annovis Bio's Price Target to $30 From $40, Keeps Buy Rating
MT
Brookline Capital Starts Annovis Bio at Buy With $35 Price Target
MT
Annovis Bio, Inc. Receives Positive Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board
CI
HC Wainwright Initiates Annovis Bio at Buy With $40 Price Target
MT
Ladenburg Thalmann Initiates Annovis Bio at Buy with $37 Price Target
MT
Maxim Group Adjusts Annovis Bio Price Target to $26 From $70, Maintains Buy Rating
MT
ANNOVIS BIO : Maxim Adjusts Annovis Bio's PT to $45 from $12, Keeps Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANVS Stock
  4. News Annovis Bio, Inc.
  5. Analyst Reco.